Thomas Tibbitts

Thomas Tibbitts, CEO and Head of Research and Development. Over twenty years experience in the pharmaceutical industry. Goldfinch Bio SVP Computational Research, launched the Kidney Genome Atlas. Third Rock Ventures team launching Goldfinch Bio with $55M series A. Infinity Pharmaceuticals, multiple drug programs over a decade Copiktra (duvelisib), approved to treat CLL and SLL, Eganelisib (IPI-549), for the treatment triple-negative breast cancer. PhD Biophysics from Brandeis University.